Enforcement record
指定 disclosure naming 富士フイルム株式会社
This page records one action from a Japanese government disclosure, including the published name, governing law, authority, action details, and official source.
Action type
指定
Law
Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices
Authority
Ministry of Health, Labour and Welfare
Action date
28 February 2017
Current page: Enforcement record
This screen focuses on one disclosed action: the published name, governing law, authority, facts, source status, and review evidence.
Source verification
Public-source and preservation status
- Publishing authority
- Ministry of Health, Labour and Welfare
- Official source URL
- Recorded by RegBase
- Entity match
- Not confirmed; shown under the published name
- Kiroku preservation
- Queued for preservation
- Captured: May 2, 2026, 09:01 PM JST
“Confirmed” means that RegBase matched this record to the cited public disclosure or entity under the stated checks. It does not verify the truth of the disclosure or guarantee the entity’s current status, creditworthiness, or any legal conclusion.
Available sources and saved files are listed in the public documents section below.
Public documents and saved materials
View the original publications, see what was preserved, or download each file below.
Loading materials…
Action summary
- Company
- 富士フイルム株式会社Japanese onlyOriginal: 富士フイルム株式会社
- Governing law
- Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices薬機法
- Action type
- 指定指定
- Action date
- 28 February 2017
- Issuing authority
- Ministry of Health, Labour and Welfare厚生労働省
- Industry context
- 医療機器
Violation
The designated medical device program by Fuji Film Corporation, which assists in predicting the effectiveness of cardiac resynchronization therapy, was specified under the Pharmaceutical and Medical Device Act (薬機法) on February 28, 2017. The program is categorized as a medical device industry. No penalties or affected consumer counts are specified.
Show original Japanese text
心臓再同期療法の効果予測の判断を補助する医療機器プログラムである。
Compliance context
Context neededThis is a public Japanese regulatory disclosure. The exact legal effect depends on the cited source and regulator.
Health product law covering pharmaceuticals, medical devices, cosmetics, quasi-drugs, labeling, and advertising.
Review the original Japanese source and determine relevance to your counterparty-risk workflow.
This context is an operational aid for review workflows, not a credit opinion or legal conclusion.
Language
日本語版を見る (Japanese)About this recordAggregated and translated from public Japanese government disclosures. The English text is for reference only — authoritative content is the linked Japanese source.